

wherein

R^1 is hydrogen, C_{1-6} -alkyl, C_{3-6} -cycloalkyl, C_{1-6} -alkoxy, halogen, $-CF_3$, or $-OCF_3$;

R^2 is $-NR^6R^7$, wherein

R^6 is hydrogen, C_{1-6} -alkyl, C_{3-6} -cycloalkyl, or C_{2-4} -acyl,

R^7 is hydrogen, C_{1-6} -alkyl, C_{3-6} -cycloalkyl, or C_{2-4} -acyl, or

R^6 and R^7 together with the nitrogen between them form a 5- or 6-membered, saturated or unsaturated ring containing 0, 1, or 2 additional heteroatoms selected from the group consisting of oxygen, sulfur, and nitrogen, wherein each additional nitrogen atom is unsubstituted or substituted by C_{1-4} -alkyl, or R^6 and R^7 together with the nitrogen between them form phthalimido;

R^3 is hydrogen, halogen, C_{1-6} -alkyl, C_{1-6} -alkoxy, $-CF_3$, or $-OCF_3$;

R^4 is hydrogen, halogen or C_{1-6} -alkyl; and

R^5 is hydrogen, C_{1-6} -alkyl, C_{1-6} -alkoxy, halogen, $-CF_3$, or $-OCF_3$;

or a pharmaceutically acceptable salt thereof.--

--22. (new) The compound of the formula II according to claim 21, wherein:

R^1 is hydrogen, C_{1-4} -alkyl, cyclopropyl, C_{1-4} -alkoxy, halogen, $-CF_3$, or $-OCF_3$;

R^2 is $-NR^6R^7$, wherein

R^6 is hydrogen, C_{1-4} -alkyl, C_{3-6} -cycloalkyl, or acetyl,

R^7 is hydrogen, C_{1-4} -alkyl, C_{3-6} -cycloalkyl, or acetyl, or

R^6 and R^7 together with the nitrogen between them form phthalimido;

R^3 is hydrogen, halogen, C_{1-4} -alkyl, C_{1-4} -alkoxy, $-CF_3$, or $-OCF_3$;

R^4 is hydrogen, C_{1-4} -alkyl, or halogen; and,

R^5 is hydrogen, C_{1-4} -alkyl, C_{1-4} -alkoxy, halogen, $-CF_3$, or $-OCF_3$;

or a pharmaceutically acceptable salt thereof.--

--23. (new) The compound of the formulae II according to claim 21, wherein:

R^1 is hydrogen, C_{1-3} -alkyl, *n*-butyl, isobutyl, *sec*-butyl, cyclopropyl, C_{1-3} -alkoxy, halogen, or $-CF_3$;

R^2 is $-NR^6R^7$, wherein

R^6 is hydrogen, C_{1-4} -alkyl, or cyclopropyl,

R^7 is hydrogen or C_{1-4} -alkyl, or

R^6 and R^7 together with the nitrogen between them form phthalimido;

R^3 is hydrogen, C_{1-3} -alkyl, *n*-butyl, isobutyl, *sec*-butyl, C_{1-3} -alkoxy, halogen, or $-CF_3$;

R^4 is hydrogen, C_{1-3} -alkyl, *n*-butyl, isobutyl, *sec*-butyl, or halogen; and,

R^5 is hydrogen, C_{1-3} -alkyl, *n*-butyl, isobutyl, *sec*-butyl, C_{1-3} -alkoxy, halogen, or $-CF_3$;

or a pharmaceutically acceptable salt thereof.--

--24. (new) The compound of the formulae II according to claim 21, wherein:

R^1 is hydrogen or methyl;

R^2 is $-NR^6R^7$, wherein

R^6 is hydrogen or methyl,

R^7 is hydrogen or methyl, or

R^6 and R^7 together with the nitrogen between them form phthalimido;

R^3 is hydrogen, methyl, fluorine, chlorine, or bromine;

R^4 is hydrogen; and

R^5 is hydrogen, methyl, chlorine, or bromine;

or a pharmaceutically acceptable salt thereof.--

--25. (new) A compound selected from the group consisting of:

2-(3-dimethylamino-2-methylphenylimino)imidazolidine,

2-(6-bromo-3-dimethylamino-2-methylphenylimino)imidazolidine,

2-(5-amino-2-chloro-4-dimethylamino-2-methylphenylimino)imidazolidine, and

2-(3-amino-2-methylphenylimino)imidazolidine,

or a pharmaceutically acceptable salt thereof.--